A case of dilated cardiomyopathy in a young boy secondary to type II 3-methylglutaconic aciduria is described. A metabolic cause for his dilated cardiomyopathy was suspected because of the development on the electrocardiogram of an unusual "camel's hump" shape of the T waves, and of progressive thickening with increasing echogenicity of the left ventricular wall. He initially improved on digoxin treatment, but did not maintain the response with conventional dietary treatment for this condition. Supplementation with L-carnitine was associated with rapid deterioration in cardiac state, and may be contraindicated in this condition. At a point when the patient was moribund, large doses ofpantothenic acid, a precursor of coenzyme A, produced a dramatic and sustained improvement in myocardial function and in growth, neutrophil cell count, hypocholesterolaemia, and hyperuricaemia, which suggests that limitation of availability of coenzyme A is a fundamental pathological process in this condition. The clinical improvement has been maintained for 13 months, and myocardial function is now nearly normal. Oral pantothenol, unlike pantothenic acid, is not efficacious.
In 1991 Kelley et al described the association of a dilated cardiomyopathy with growth failure, neutropenia, and a low serum cholesterol occurring in five pedigrees with an inheritance suggestive of an X linked disorder.' The disorder was associated with increased urinary excretion of 3-methylglutaconic and 3-methylglutaric acids. Subsequently the condition has been separated from other phenotypic manifestations of more severe 3-methylglutaconic aciduria and termed the type II syndrome.2 Death may occur from heart failure or sepsis in early life, but survival to late childhood and possibly adulthood in untreated patients has been reported.' 3- Methylglutaconate is an intermediate in the catabolism of leucine, but whereas the primary metabolic defect in type I 3-methylglutaconic aciduria has been described-namely, 3-methylglutaconic coenzyme A hydralase deficiency-no specific defect in the type II presentation has as yet been identified. ' Accordingly, suggested dietary treatment is entirely empirical. We describe here the electrocardiographic features and the response to various dietary modifications and supplements in a case presenting with neonatal heart failure.
Case report A boy with a birth weight of 2-76 kg was born after prolonged labour; frequent fetal bradycardias necessitated a venthouse extraction. Apgars were 9,10,10. There were no immediate neonatal problems, but he was readmitted to hospital with gross congestive heart failure at the age of 3 weeks. Chest x ray film showed considerable cardiomegaly and the electrocardiogram showed right atrial hypertrophy, left ventricular dominance with dominant S in V1, 12 mm R in V6, and generalised T wave flattening. Initial echocardiography showed a normal cardiac anatomy but grossly dilated right and left ventricles with a severely reduced left ventricular ejection fraction (22%) and severe, presumed functional, incompetence of both tricuspid and mitral valves. The coronary arteries were normal, and there were no strong endocardial echoes typical of endocardial fibroelastosis. His mother had had a viral illness two to three weeks before delivery and the differential diagnosis was thought to be "transient myocardial ischaemia of the newborn" or perinatal myocarditis. The baby was treated by rapid oral loading with digoxin, frusemide, and spironolactone and his clinical condition rapidly improved. Viral studies from mother and infant were negative.
After one month of digoxin treatment his ejection fraction had improved to 49%, and both tricuspid and mitral valve incompetence had disappeared. The T waves on the electrocardiogram were generally more upright ( fig  1 (A) ). The ejection fraction continued to improve reaching a peak of 59% at 6 months of age (fig 2(A) ) and it was thought likely that his cardiomyopathy was due to a perinatal insult. Initial weight gain was relatively satisfactory with weight remaining on the third centile and height along the 10th centile, but around 6 months of age weight gain began to fall off the third centile (fig 2(C) ) and height and head circumference dropped to the third centile. There were no symptoms or signs of congestive heart failure. He was a poor eater, taking only small amounts of solids, and often had respiratory tract infections. After 12 months of age the electrocardiogram started to show increasing T wave abnormalities with Figure 1 (A) Development of T wave abnormalities and left ventricular hypertrophy in the period before pantothenic acid treatment. The first line of complexes shows the electrocardiogram at presentation with heart failure at 3 weeks of age. The T waves are generally flat, the QT interval 0-32 s and QTc 0-46s. Sokolow-Lyon index (S in Vl plus R in V6) = 30 mm. The second line of complexes shows the electrocardiogram at three months of age; T waves are more normal but the R wave in V6 is increased at 24 mm. The QT interval is 0-29 s and QTc 0 43s. Sokolow-Lyon index = 36 mm. The third line of complexes shows the electrocardiogram at the age of 18 months, shortly before the diagnosis was made. The appearance of the T wave is unusual with a very early onset of the T wave, only 0-06 s after the beginning of the QRS complex, and with a camel's hump notch after the maximum T wave amplitude. The QT interval is 0 30 s and QTc remains long at 0 44s. Thus there is increasing difference in the duration of the action potential in different parts of the myocardium with some areas having a very short duration.
Sokolow-Lyon index = 46 mm. The fourth linle shows the electrocardiogram at the age of 22 months, on dietary treatment, but before starting pantothenic acid. The T waves are still notched, but generally flatter so that the duration of the QT interval is difficult to measure accurately; the QTc seems shorter than before at about 0 39s. There is considerable increase in voltages with a Sokolow-Lyon index of 58 mm. Over the next two months there was a dramatic further increase in voltages with the Sokolow-Lyon index reaching 93 (fig 2(B) ), and a moderate improvement in ejection fraction (fig 2(A) ). The left ventricle remained dilated and mitral valve incompetence remained severe. Then, inexplicably, after six weeks the patient's appetite deteriorated and he started to lose weight (fig 2(C) group.bmj.com on July 8, 2017 -Published by http://heart.bmj.com/ Downloaded from moderate, the metabolite was probably derived from a small body pool rather than a large body pool as in the type 1 syndrome. Furthermore, as 3-methylglutaconic acid derives from the coenzyme A ester, there could be a consequent sequestration of coenzyme A in a small, specific body pool. Given the overriding cardiac presentation of the patient, this pool might be the myocardium. Sequestration of coenzyme A might compromise that organ's ability to oxidise its normal metabolic fuels, namely free fatty acids and glucose, giving rise to impaired cardiac contractility.
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The patient's diet was therefore changed. The principles were to reduce the leucine content (the milk formula changed to Paedisure), to r'educe the medium chain triglyceride supplement, to add carbohydrate supplement, and to change the vitamin supplement from Vitamin B compound Strong to a preparation that contained pantothenic acid, the precursor of coenzyme A. The only commercial preparation available containing large amounts of pantothenic acid was the intravenous preparation Solivito N which was given orally. The response was dramatic: the child started to pass urine, overt heart failure disappeared over two days, and the ejection fraction improved to 28%. The improvement was maintained and his appetite improved. Subsequently, we attempted to move to a commercial oral vitamin preparation, but could identify only one containing large doses of any derivative of pantothenic acid, namely Vigranon B. This contains racemic pantothenol (panthenol), the alcohol derivative of pantothenic acid. This was fed together with other vitamin supplements to give at least equivalent vitamin supplements to that obtained from Solivito N. Two days after changing to pantothenol, however, the child was in gross heart failure again and was unresponsive to parenteral diuretics. The next day he remained gravely ill and pantothenol was changed to pantothenic acid (Solivito N) again. There followed a steady and maintained improvement. As the only relevant change in his diet at this time was the exchange of pantothenic acid for panthenol, and there was no intercurrent illness to account for his deterioration, it seemed that he was unable to use pantothenol, the alcohol form of the coenzyme A precursor.
After (fig 2(A) ), and' eventual complete disappearance' of mitral incompetence. Furthermore echocardiographic estimates suggests a 65% reduction in left ventricular mass since the start of the panthothenic acid supplement. The start of the pantothenic acid supplement was also associated with a considerable increase in neutrophil count (fig 2(B) ), both absolute and as percentage of total white cell count. Hypocholesterolaemia and hyperuricaemia have also improved (cholesterol 4-0 mmol/l; uric acid 149 ,umol/l).
Discussion
We present a child with type II X linked 3-methylglutaconic aciduria who showed no sustained improvement in cardiac function despite conventional dietary and drug treatment. The introduction of pantothenic acid to the therapeutic regimen resulted in a dramatic clinical improvement. This therapeutic approach was based upon the hypothesis that there was a compromised tissue supply of coenzyme A, perhaps particularly affecting the heart's ability to use its main metabolic fuels-namely free fatty acids and glucose.
There are several possible mechanisms that might explain the efficacy of pantothenic acid. It is often stated that a supplement of L-carnitine is totally without risks or side effects, and that it might be beneficial not only in primary camitine deficiency, but also in secondary carnitine deficiencies-for example, organic acidurias such as 3-methylglutaconic aciduria.'0 In this boy, however, several clinical variables showed accelerated deterioration with the carnitine supplement. In particular, there was a rapid increase in left ventricular wall thickness as well as left ventricular end diastolic diameter. As both were reversible with pantothenic acid supplement it suggests that there was an accumulation of some intermediate metabolite within the myocardium.
L-Carnitine is an essential cofactor in the translocation of free long chain fatty acids into the mitochondrial matrix,' and this process also requires cytoplasmic fatty acylcoenzyme A, whereas subsequent intramitochondrial catabolism of fatty acids requires coenzyme A. Thus if the availability of coenzyme A is limited, a dietary supplement of L-carnitine alone will not lead to any clinical improvement. Indeed, the possible production and accumulation within the mitochondria of abnormal metabolites may lead to a deterioration in tissue functions as occurred here, and the thickening of the left ventricular wall may reflect just such a process. Hence, it would seem prudent to exclude 3-methylglutaconic aciduria and perhaps. other organic acidurias, before therapeutic trials with L-carnitine are attempted in cases with dilated cardiomyopathy of possible metabolic origin.
DIGOXIN
It is a recurrent finding from previous case histories that digoxin has a clearly beneficial effect on myocardial contractility in 3-methylglutaconic aciduria.' This effect has been strikingly shown in this case too, although the initial improvement in ejection fraction from 22% to 59% (fig 2(A) ) was not maintained when the left ventricular wall started to show pathological thickening, presumably caused by accumulation of abnormal metabolites.
The responsiveness to digoxin, together with the oddly shaped T waves on the electrocardiogram, lead us to consider whether 3-methylglutaconic aciduria is associated with abnormalities in plasma membrane sodiumpotassium ATPase. Screening for the efficacy of the ATPase by subjecting red cells to osmotic stress showed the reverse, namely that this patient's red cells show a reduced sensitivity to osmotic stress, a finding that at the moment remains unexplained, but is particularly interesting in relation to his haemolytic crisis.
DRUG INDUCED HAEMOLYSIS
Initially we suspected that the boy's haemolysis was due to glucose-6-phosphate dehydrogenase deficiency as this is also an X linked condition. Further investigations have, however, shown normal glucose-6-phosphate dehydrogenase and 6-phosphogluconate dehydrogenase activities. Thus both the mechanism and the agent in the Seravit preparation responsible for the episode of haemolysis remain unknown. It is, however, unlikely to have been caused by vitamins C or D, or the B complex vitamins as the patient continues to tolerate normal or increased doses of these in other vitamin preparations.
In conclusion there is little doubt that large doses of pantothenic acid (a precursor of coenzyme A) were life saving in this patient. Provision of this rate limiting substrate for coenzyme A synthesis has led to improvement not only in myocardial contractility, but also to neutrophil cell counts and hypocholesterolaemia, suggesting that limitation of availability of coenzyme A is a fundamental pathological process in type II 3-methylglutaconic aciduria. As shown here a sustained improvement can be obtained with manipulation of the diet and a supplement of pantothenic acid and the condition is notably responsive to digoxin treatment. Thus, all cases of idiopathic dilated cardiomyopathy ought to be screened for metabolic causes. In particular, male patients of all ages should be screened for 3-methylglutaconic aciduria. Associated features suggesting the diagnosis include neutropenia, hypocholesterolaemia, and hyperuricaemia.
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